The aim of the present study was to investigate the mechanisms of CCAAT/enhancer-binding protein β (C/ EBPβ) in cardiac myofibroblast (CMF) differentiation and in a rat model of cardiac fibrosis induced by experimental autoimmune myocarditis (EAM).
M yocardial fibrosis is a key cause of heart failure, malignant arrhythmias and other cardiovascular events. [1] [2] [3] It is characterized as an accumulation of collagen fibers; a significant increase in collagen concentration, and a change in the composition of collagen components in myocardial tissue. Myocardial fibrosis is a nearly inevitable outcome in end-stage cardiovascular disease, which results in cardiac structural remodeling due to excess extracellular matrix (ECM). [4] [5] [6] The ECM is mainly composed of type I and type III collagen. Approximately 85% of total myocardial collagen is type I, while type III collagen accounts for 11% of the total collagen protein. 7, 8) During fibrosis, quiescent cardiac fibroblasts (CF) become activated and differentiate into cardiac myofibro-blasts (CMF), which typically express α-smooth muscle actin (α-SMA) and acquire the ability to proliferate, migrate, and produce ECM. 1, 9, 10) Fibroblast to myofibroblast differentiation is a key process during cardiac remodeling. Transforming growth factor-beta 1 (TGF-β1) plays an important role in the transdifferentiation of CF into CMF, which is an important mediator of myocardial fibrosis. 11) Independent studies have also suggested myocardial inflammation is a mechanism that also leads to the development of cardiac fibrosis, [12] [13] [14] and is intimately linked to myocardial fibrosis leading to heart failure. 6, 13) Compelling evidence suggests that C/EBPβ is an important regulator of cell proliferation, differentiation and apoptosis, 15, 16) and can also significantly attenuate fibrosis in the liver and lung; 17, 18) however, the impact and mecha-Li, ET AL nisms of C/EBPβ in CMF and CF remain elusive. The aim of the present study was to examine the effects of C/ EBPβ knockdown in primary neonatal rat CF and a rat model of cardiac fibrosis induced by experimental autoimmune myocarditis (EAM) using a lentiviral shRNA approach.
Methods

C/EBPβ lentiviruses:
Lentiviruses containing small hairpin RNA (shRNA) (Lenti-shC/EBPβ) directed against C/ EBPβ (shRNA sequence: GAAGAAACGTCTATGTGTA) were obtained from Genechem (Shanghai, China). Lentivirus containing vector was used as control. C/EBPβ lentiviral studies in cardiac myofibroblast cultures and rat EAM model: For in vitro studies, rat cardiac fibroblasts were isolated from 3-day-old neonatal Sprague-Dawley rat pups using a differential adhesion method as described previously. 19) Cells were centrifuged after digestion and suspended in Dulbecco's Modified Eagle's Medium (DMEM; Hyclone, Logan, CT) supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan, CT), and then plated on dishes in DMEM at 37 and 5% CO2. After 1 hour, the adhered CF were cultured in DMEM containing 10% fetal calf serum (hyclone). The CF were subdivided into 4 groups: (1) Control group; CF with no treatment, (2) Mock group (TGFβ1 group); CF treated with TGF-β1 (10 ng/mL) for 72 hours (to induce the transition from cardiac fibroblasts to myofibroblasts), (3) Vector group (TGF-β1 + lentiviral vector group); CF treated with TGF-β1 (10 ng/mL) and infected with a control lentivirus for 72 hours, and (4) Lenti-shC/EBPβ group (TGF-β1 + Lenti-shC/EBPβ group); CF treated with TGF-β1 (10 ng/mL) and infected with a lentivirus harboring a shRNA to C/EBPβ for 72 hours, in order to investigate the effect of Lenti-shC/EBP on the transformation of CF into CMF.
For in vivo studies, the animals were randomly divided into 4 groups (n = 6 rats/group) (1): Saline group; injected in the footpad with saline alone, (2) Negative control group (EAM group); injected in the footpad with the emulsion and developed myocarditis, (3) Positive control group (EAM + Lentiviral Vector); injected in the footpad and developed myocarditis and subsequently infected at day 28 with a control lentivirus, and (4) Experimental group (EAM + Lenti-shC/EBPβ); rats developed myocarditis and subsequently infected with a lentivirus con-taining a shRNA to C/EBPβ. For lentivirus administration, the rats were anaesthetized with chloral hydrate (0.3 mL/ 100 g body weight) and immobilized to isolate the femoral vein for lentiviral injection. Rats were injected in the femoral vein with 0.2 mL of a control lentivirus (10 8 ) (SonoVue as carrier) or a lentivirus harboring shRNA to C/EBPβ (10 8 ) (SonoVue as carrier) using an ultrasoundtargeted microbubble gene therapy technique. 20) Rats that did not undergo lentiviral injection were not subjected to transthoracic ultrasound irradiation ( Figure 1 ). In vivo study: Animals and immunization protocol These studies were performed at Harbin Medical University and approved by the Experimental Animal Care and Use Committee of Harbin Medical University. Twenty-four inbred male Lewis rats (5 weeks, 180-200 g) were purchased from Beijing Vital River Laboratory Animals Co. Ltd. (Beijing, China) and housed under specified pathogen free conditions.
Cardiac myosin purified from porcine heart (9.8 mg/ L; Sigma, CO) was emulsified with an equal volume of complete Freund's adjuvant (CFA; Sigma, CO), which was supplemented with Mycobacterium tuberculosis H37 RA (Difco, USA). Rats were injected with either saline (Saline) or this emulsion (0.2 mL; EAM) in the footpad on days 0 and 7 to induce an experimental autoimmune myocarditis model, as described previously. 21) Echocardiography Four weeks after lentiviral infection, echocardiography was performed on the rats as described previously. 22, 23) Briefly, the rats were anesthetized with chloral hydrate and subjected to transthoracic echocardiograms using a General Electric (GE, Vivid-5) imaging system equipped with a 1.7-3.6 MHz multi-frequency transducer in order to measure interventricular septal wall thickness at end diastole (IVS), left ventricular posterior wall thickness (LVPW), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), ejection fraction (EF), and fractional shortening (FS).
Cardiac histology with HE staining and Masson's staining
Heart tissue was harvested from anesthetized rats. The left ventricles were separated and sectioned transversely into 4 slices from apex to base. All slices were formalin-fixed, paraffin-embedded, and sectioned into 5 μm thick sections. Deparaffinized rat heart tissue sections were then subjected to hematoxylin and eosin staining or Masson's trichrome stain according to the manufacturer's protocols. 
THE ROLE OF C/EBPβ IN CARDIAC FIBROSIS
The inflammation-affected or fibrosis-affected area in each region was counted in a high-powered field (× 400) by an investigator who was blinded to the studies and expressed as the percentage of inflammation-affected or fibrosisaffected area/total area. Immunohistochemical staining Deparaffinized rat heart tissue sections were incubated with 3% hydrogen peroxide, and then incubated with primary antibodies to C/EBPβ (1: 1000; Santa Cruz Biotechnology, Dallas, TX), MMP-2 (1: 200, Santa Cruz Biotechnology), MMP-9 (1:200, Santa Cruz Biotechnology), Col I (1:200, Santa Cruz Biotechnology), Col III (1:200, Santa Cruz Biotechnology), and α-SMA (1:200, Santa Cruz Biotechnology). Subsequently, sections were incubated with a goat anti-mouseconjugated peroxidase-labeled secondary antibody (1: 1000; Santa Cruz Biotechnology) for 30 minutes at room temperature. Positive signals were visualized using a diaminobenzidine substrate chromagen solution and hematoxylin counterstain.
In vitro study:
Immunofluorescence microscopy analyses CMF were rinsed 3 times with PBS and fixed with 4% paraformaldehyde and subjected to 0.1% Triton X-100 (Beyotime Biotechnology, Shanghai, China) in PBS for 20 minutes at 20 . Cells were then washed 3 times with PBS and incubated with antibodies against cofilin (1:50; Boster, Wuhan, China) and FLNA (1:50; Sangon, Shanghai, China). Fluorophore-tagged secondary antibodies and a fluorescent microscope (Olympus BX61) were utilized for protein visualization and imaging. The fluorescence intensity was analyzed using Image-pro plus 6.0 (Media Cybernetics). Quantitative RT-PCR analysis of C/EBPβ, cofilin and FLNA mRNA Total RNA was extracted from CMF using TRIzol (Life Technologies, Rockville, MD) according to the manufacturer's protocol. cDNA was produced using M-MLV Reverse Transcriptase (Promega) according to the manufacturer's recommendations for oligo (dT) 20 or random hexamer primed cDNA-synthesis. cDNA synthesis was performed using 1 μg of RNA at 40 . Finally, cDNA was diluted 1:5 before use in qPCR. Samples were then subjected to a quantitative polymerase chain reaction using a 7300 Real-Time PCR system (Applied Biosystems) and specific SYBR green primers (Table I ; Invitrogen Life Technologies, Carlsbad, CA, USA), according to the manufacturer's protocols. Samples underwent the following PCR reaction conditions, which included an initial denaturation stage (45 , 2 minutes; 95 , 10 minutes) followed by 40 cycles, each cycle containing 3 steps (denaturation 95 , 15 s; annealing 60 , 1 minutes; and ex-tension 72 , 1 minutes). Glyceraldehyde phosphate dehydrogenase (GAPDH) was evaluated as an internal control and the quantification of C/EBP-β, FLNA and cofilin mRNA relative to GAPDH was assessed. Each reaction was analyzed in triplicate. Western blot analysis of C/EBPβ, LAP, LIP and collagen Protein concentrations of the samples were determined using the Lowry method. 24) Proteins (50 μg) were separated by 12% SDS-polyacrylamide gel and transferred onto nitrocellulose membranes, which were blocked with TBST buffer containing 5% skim milk. Membranes were then incubated with primary antibodies directed against C/ EBPβ (1:500; Santa Cruz Biotechnology), LAP isoform (1:500; Santa Cruz Biotechnology), and LIP isoform (1: 500; Santa Cruz Biotechnology) overnight at 4 . The appropriate HRP-conjugated secondary antibodies (Wanleibio, China) were used to amplify the signals of primary antibodies. Then the ECL western blotting detection reagent (Wanleibio, China) was used to display the content of protein and quantified by Image J Software. Enzyme-linked immunosorbent assay (ELISA) The levels of inflammatory mediators were quantified using specific ELISA kits for each group (Control, Mock, Vector and Lenti-shC/EBPβ group) according to the manufacturers' protocols (tumor necrosis factor alpha (TNF-a), interleukin-1β (IL-1β), interleukin-6 (IL-6), from Merck Millipore, MA, USA). Statistical Analysis All data are expressed as the mean ± standard deviation. Statistical comparisons were performed using one-way analysis of variance (ANOVA) followed by Tukey's post hoc test for multiple comparison (Graphpad Prism, version 5.0). P values of less than 0.05 were considered statistically significant.
Results
In vitro:
Lenti-viral shRNA approaches are sufficient to significantly reduce C/EBPβ mRNA and protein expression in CMF To investigate the role of C/EBPβ in CF differentiation, we used a lentivirus harboring C/EBPβ shRNA (Lenti-shC/EBPβ). Quantitative RNA analysis of TGF-β1 treated CF that were infected with Lenti-shC/EBPβ resulted in significant reductions in C/EBPβ mRNA, cofilin mRNA, and FLNA mRNA levels compared to the control (control, mock and vector) groups (Figure 2 ). Protein blot analyses of CMF infected with Lenti-shC/EBPβ also demonstrated significant decreases in C/EBPβ-(LAP+LIP), C/ EBPβ-LAP, and C/EBPβ-LIP protein expression ( Figure  3 ). C/EBPβ knockdown could attenuate cytoskeletal remodeling in CMF To determine the role of C/EBPβ on cytoskeletal switching and remodeling in CMF, CMF were infected with Lenti-shC/EBPβ. We observed that C/EBPβ knockdown significantly attenuated cofilin and FLNA mRNA expression in CMF when compared with controls (not infected with Lenti-shC/EBPβ) ( Figure 4 ). Thus, knockdown of C/EBPβ can attenuate actin cytoskeletal remodeling in CMF in vitro. C/EBPβ knockdown could reduce inflammatory markers As shown in Table II , there was a marked increase in the Li, ET AL levels of the inflammatory markers IL-1β, IL-6, and TNFa in the Mock group and the Vector group compared with the Control group. Administration of Lenti-C/EBPβ reduced the above-mentioned inflammatory mediators (Table  II) .
In vivo: C/EBPβ knockdown attenuated cardiac inflammation and fibrosis in EAM rats
To determine the role of C/EBPβ on cardiac remodeling in a rat model of EAM, rats were injected with Lenti-shC/EBPβ in vivo and histopathological analyses were performed ( Figure 5 ). C/EBPβ knockdown attenuated fibrotic markers in EAM rat hearts We performed immunohistochemical assessment of collagen I, collagen III, MMP-2, MMP-9, α-SMA, and C/EBPβ in rat heart tissues. We observed that collagen I, collagen III, MMP-2, MMP-9, α-SMA, and C/EBPβ protein expressions are increased in heart tissue sections from EAM rats (EAM group and EAM + Lentiviral Vector group), when compared to the Control group ( Figure 6 ). Furthermore, C/EBPβ knockdown attenuated the C/EBPβ protein expression as well as expression of collagen I, collagen III, MMP-2, MMP-9, and α-SMA in heart tissue sections from rats in the EAM + Lenti-shC/EBPβ group ( Figure 6 ). These results indicate that C/EBPβ knockdown is capable of dampening inflammation mediated induction of α-SMA and collagen production, suggesting that C/ EBPβ is critical in myofibroblast differentiation.
C/EBPβ knockdown improved cardiac dimensions and function in EAM rats
To determine the role of C/EBPβ on heart structure and function in the rat EAM model, we performed echocardiography on rats in the Control, EAM, EAM+ Lentiviral Vector, and EAM+Lenti-shC/EBPβ groups. We observed cardiac hypertrophy, wall thinning, and cardiac dysfunction in rats in the EAM and EAM+ Lentiviral Vector groups. However, C/EBPβ knockdown could significantly improve cardiac dimensions and function in rats in the EAM+ Lenti-shC/EBPβ group (Table  III) .
Discussion
Myocarditis is a pivotal cause of sudden death among young adults. 26) It is also often the vaunt-courier of cardiac remodeling and heart failure. The rat EAM model is one that recapitulates immuno-inflammatory cardiac remodeling (fibrosis). 27) Myocardial fibrosis plays a principal role in the pathophysiology of heart failure; however, the mechanisms driving inflammation-mediated cardiac fibrosis remain unclear. C/EBPβ is an important regulator of genes involved in immune and inflammatory responses, but recent evidence also suggests that its loss can attenuate fibrosis in the lung and liver, 17, 18) highlighting its po-THE ROLE OF C/EBPβ IN CARDIAC FIBROSIS TNF-a indicates tumor necrosis factor alpha (pg/mL); IL-1β, interleukin-1β (pg/mL); and IL-6, interleukin-6 (pg/mL). *P < 0.05 versus the Control group and the Lenti-C/ EBPβ group.
Li, ET AL tential as a novel therapeutic target for regulating the immuno-inflammatory tissue fibrotic response. TGF-β1 is a potent driver of myofibroblast differentiation from various progenitor cells, primarily resident fibroblasts. The findings of this study suggest that TGF-β1 mediated myofibroblast differentiation is sensitive to changes of C/EBPβ knockdown as shown by the reduction of actin regulatory protein expression. Cofilin and FLNA are newly discovered members of the actin regulatory protein family. 27, 28) FLNA binds to F-actin and induces high-angle crosslinking to provide a strong 3dimensional cytoskeletal structure. [29] [30] [31] Studies have described the importance of actin polymerization/depolymerization as key mediators of CMF phenotype transformation. 32, 33) Specifically, polymerization/depolymerization of α-SMA is controlled by the actin depolymerizing factor (ADF)/cofilin family, which binds polymerized actin (Factin) and breaks it down into G-actin by depolymerization, thereby regulating the stability and function of α-SMA. 34) We found that C/EBPβ knockdown could reduce the protein expression of cofilin and FLNA, suggesting that the cofilin/FLNA signaling pathway may be a downstream effector of C/EBPβ during CF differentiation. C/EBPβ is an intronless gene that codes for the production of a single mRNA. The C/EBPβ mRNA transcript can translate into 4 different protein isoforms: full length C/EBPβ or LAP * (liver-enriched transcriptional activating protein star) with an atomic mass of 38 kDa, LAP (liverenriched transcriptional activating protein), which has an atomic mass of 35 kDa, the 20 kDa isoform LIP (liverenriched transcriptional inhibitory protein), and a smaller 16 kDa isoform. The isoform LAP is a transcriptional activator, while the isoform LIP, which lacks the transactivation domain, is a transcriptional inhibitor. 35) C/EBPβ mRNA can be translated into two isoforms, which include LAP (LAP*) and LIP. LIP lacks the activation domain and is thus thought to be the dominant negative isoform of LAP. 36 dicator for C/EBPβ activity. Our studies demonstrated an increase in the LAP/LIP ratio in C/EBPβ knockdown studies. It is possible that although both LAP and LIP isoforms were targeted by the C/EBPβ shRNA lentivirus; that LIP may be more impacted than LAP. The C/EBPβ lentivirus inhibits LAP as well as LIP. These two come from the same mRNA. However, because the molecular activity of LIP is much higher than LAP, the degree of inhibition of LIP would be more significant than that of LAP. Therefore, sh-C/EBPβ impacts LIP more than LAP. 37) Some studies have demonstrated that increasing LIP isoform expression may have the capacity to control LAP activity, resulting in a decrease in the LAP/LIP ratio, and decreased α-SMA expression. 38) Recently, it has been found that the regulation of a-SMA expression and polymerization is the key to the phenotypic transformation from fibroblasts into myofibroblasts. 10) These processes are regulated by serum response factor (SRF). The actin gene regulatory region of a-SMA contains the CArG box element. 39, 40) SRF regulates a-SMA through this regulatory element. 41) In unpublished results, we found the pretreatment of CF with the SRF blocker CCG-1423 could significantly inhibit C/EBPβ induced CF differentiation. This suggested that SRF may be involved in C/EBPβ induced CF transformation. The SRF gene regulatory region contains CCAAT binding element, which specifically binds to C/EBPβ and regulates the expression of target gene. 42) SRF is a weak transcriptional activator, which plays a role in the regulation of gene expression. It can promote the transcription factor to form the complex, and thus initiate transcription of the target gene. 43) The dependence on transcription factors is the basic action model of SRF. We speculate that transcription factor complex C/EBPβ-SRF plays an important role in differentiation from CF into CMF. However, further study is needed to verify the possible interactions between C/ EBPβ and SRF protein, and the effects of this interaction on the expression of a-SMA and its polymerization and depolymerization. Cardiac fibroblasts play a crucial role in extracellular matrix regulation as they produce structural proteins that comprise the extracellular matrix, such as collagen, as well as promote their degradation by secreting MMP proteins. We provide evidence that C/EBPβ knockdown in a rat EAM model significantly attenuated cardiac collagen I, collagen III, MMP-2, and MMP-9 protein levels. C/EBPβ knockdown also impacted the fibroblasts inflammatory response as indicated by IL-1β, IL-6, and TNF-a production. It is well established that members of the C/EBP family regulate target genes associated with inflammation, including many cytokines and chemokines. 17, 39, 40) Our studies also demonstrate that C/EBPβ knockdown resulted in a cardiac structural and functional improvement in the rat EAM model. Previous studies have indicated that C/EBPβ heterozygous deficient mice displayed improved cardiac function in the face of pressure overload, 41) which is consistent with our study findings.
Taken together, our findings show that C/EBPβ is a positive regulator of cardiac inflammation and fibrosis in EAM rats. We have demonstrated that C/EBPβ regulates the actin remodeling proteins cofilin and FLNA in vitro, which are impacted during CMF differentiation. These findings may impact our in vivo findings utilizing C/EBPβ shRNA lentiviral approaches in the rat EAM model, which demonstrate a role for C/EBPβ in extracellular matrix production and degradation. Thus, the cofilin and FLNA-related signaling pathways may provide a potential new therapeutic target to attenuate cardiac fibrosis. However, additional future studies are warranted to investigate the detailed mechanisms by which C/EBPβ attenuates cardiac fibrosis.
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